News
AbbVie released positive topline data from its phase 3 UP-AA trial demonstrating safety and efficacy for upadacitinib for ...
Identifying early predictors of chronic kidney disease (CKD) progression in patients with lupus nephritis may help define a high-risk group.
Biomarkers at 6-week interim analysis show a positive impact on fibrogenesis, fibrolysis and potentially the initiation of a repair response. The Independent Data Monitoring Commi ...
In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of ...
A 19-year-old woman with a history of depression and anxiety symptoms was admitted to the hospital because of seizure, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results